Accrual strategies for phase I trials with delayed patient outcome

Statistics in Medicine

Volumn 18, Issue 10, 1999, Pages 1155-1169

  Thall, Peter F ^a   Lee, Jack ^a   Tseng, Chi Hong ^a   Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DOSE CALCULATION; HUMAN; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PROBABILITY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; CLINICAL TRIALS, PHASE I; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GUIDELINES; HUMANS; INTERNET; MODELS, STATISTICAL; RESEARCH DESIGN; TIME FACTORS;

EID: 0033617666     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(19990530)18:10<1155::AID-SIM114>3.0.CO;2-H     Document Type: Article

References (18)

1. O'Quigley, J., Pepe, M. and Fisher, L. 'Continual reassessment method: a practical design for phase I clinical trials in cancer', Biometrics, 46, 33-48 (1990).
2. Gooley, T. A., Martin, P. J., Fisher, L. D. and Pettinger, M. 'Simulation as a design tool for phase I/II clinical trials: An example from bone marrow transplantation', Controlled Clinical Trials, 15, 450-462 (1994).
3. O'Quigley, J. and Chevret, S. 'Methods for dose-finding in cancer clinical trials: A review and results of a Monte-Carlo study', Statistics in Medicine, 10, 1647-1664 (1991).
4. O'Quigley, J. and Shen, L. Z. 'Continual reassessment method: a likelihood approach', Biometrics, 52, 673-684 (1996).
5. Thall, P. F., Simon, R. and Estey, E. H. 'Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes', Statistics in Medicine, 14, 357-379 (1995).
6. Thall, P. F., Simon, R. and Estey, E. H. 'New statistical strategy for monitoring safety and efficacy in single-arm clinical trials', Journal of Clinical Oncology, 14, 296-303 (1996).
7. Thall, P. F. and Russel, K. E. 'A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials', Biometrics, 54, 251-264 (1998).
8. Thall, P. F. and Sung, H-G. 'Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials', Statistics in Medicine, 17, 1563-1580 (1998).
9. Lazaridis, E. and Gonin, R. 'Continuously monitored stopping boundary methodologies: The issues of sensitivity, association and trial suspension', Statistics in Medicine, 16, 1925-1941 (1997).
10. Fanes, D. 'Practical modifications of the continual reassessment method for phase I cancer clinical trials', Journal of Biopharmaceutical Statistics, 4, 147-164 (1994).
11. Korn, E. L., Midthune, D., Chen, T. T., Rubinstein, L. V., Christian, M. C. and Simon, R. M. 'A comparison of two phase I trial designs', Statistics in Medicine, 13, 1799-1806 (1994).
12. Möller, S. 'An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses', Statistics in Medicine, 14, 911-922 (1995).
13. Goodman, S. N., Zahurak, M. L. and Piantadosi, S. 'Some practical movements in the continual reassessment method for phase I studies', Statistics in Medicine, 14, 1149-1161 (1995).
14. Estey, E. H., Hoth, D., Simon, R., Marsoni, S., Leyland-Jones, B. and Wittes, R. 'Therapeutic response in phase I trials of antineoplastic agents', Cancer Treatment Reports, 70, 1105-1115 (1986).
15. Smith, T. L., Lee, J. J., Kantarjian, H. M., Legha, S. S. and Raber, M. N. 'Design and results of phase I cancer clinical trials: three-year experience at M. D. Anderson Cancer Center', Journal of Clinical Oncology, 14, 287-295 (1996).
16. Geller, N. L. 'Design of phase I and II clinical trials in cancer a statistician's view', Cancer Investigation, 2, 483-491 (1984).
17. Storer, B. 'Design and analysis of phase I clinical trials', Biometrics, 45, 925-939 (1989).
18. deMoor, C. A., Higdon, D. M., Hilsenbeck, S. G., Clark, G. M. and von Hoff, D. D. 'Incorporating toxicity grade information in the continual reassessment method for phase I clinical trials', unpublished manuscript (1996).